ViaDerm-GLP1 agonist: Phase Ia data

Data from a 3-way crossover Phase Ia trial in 12 patients showed that 5 and 15 µg doses of ViaDerm-GLP1 agonist were well tolerated, with the higher dose displaying an extended PK profile compared to ...